MedMira Inc - Asset Resilience Ratio
MedMira Inc (MIR) has an Asset Resilience Ratio of 3.09% as of October 2002. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MedMira Inc (MIR) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2002)
This chart shows how MedMira Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is MedMira Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down MedMira Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read MIR total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$73.82K | 3.09% |
| Total Liquid Assets | CA$73.82K | 3.09% |
Asset Resilience Insights
- Limited Liquidity: MedMira Inc maintains only 3.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
MedMira Inc Industry Peers by Asset Resilience Ratio
Compare MedMira Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for MedMira Inc (2001–2002)
The table below shows the annual Asset Resilience Ratio data for MedMira Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2002-07-31 | 2.20% | CA$73.82K ≈ $53.40K |
CA$3.36 Million ≈ $2.43 Million |
-0.19pp |
| 2001-07-31 | 2.39% | CA$72.35K ≈ $52.33K |
CA$3.03 Million ≈ $2.19 Million |
-- |
About MedMira Inc
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or who… Read more